Clinical trials: Type 2 Diabetes (T2D)
Diabetes, Diabetes Mellitus, Type 2
A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
This study is conducted in Europe. The aim of the study is to investigate the effectiveness of Xultophy® (insulin degludec/liraglutide) in an adult real-world population with type 2 diabetes mellitus.
- Trial name
- NCT02754817
- Testing
- insulin degludec/liraglutide
- Where
- 5 sites in Austria, Germany and 3 more
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.
- Trial name
- CMAP (NCT02121717)
- Testing
- Chiglitazar
- Where
- 26 sites in China
- Volunteers
- 535 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diabetes Mellitus, Type 2
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).
- Trial name
- NCT01111955
- Testing
- BMS-823778, Metformin
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
- Trial name
- NCT07502508
- Testing
- icovamenib 100 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biomea Fusion Inc.
Type 2 Diabetes
Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine)
Evaluation of effect on diurnal glycaemia following consumption of MCT and whey protein in patients with type 2 diabetes
- Trial name
- NCT04905589
- Testing
- BetaQuik™, WheyBasics, Iso-voluminous water
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Société des Produits Nestlé (SPN)
Type 2 Diabetes Mellitus
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).
- Trial name
- NCT00099333
- Testing
- exenatide, Insulin
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the quality of life and clinical outcomes in subjects using NovoMix® 30 (biphasic insulin aspart 30) for the treatment of diabetes mellitus under…
- Trial name
- IMPROVE Life (NCT00696163)
- Testing
- biphasic insulin aspart 30
- Where
- India
- Volunteers
- 24,975 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
Primary Objective: To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after 6 months of treatment in patients with monotherapy until the end of the trial.
- Trial name
- SUMER (NCT00957060)
- Testing
- GLIMEPIRIDE (HOE490), SITAGLIPTIN
- Where
- 2 sites in Guatemala, Mexico
- Volunteers
- 400 people
- Sponsor
- Sanofi
Healthy Volunteers, High Blood Cholesterol Levels
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
In this study, four new tablet versions of two compounds will be investigated. The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet…
- Conditions
- Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes
- Trial name
- NCT05129891
- Testing
- Semaglutide D, Semaglutide G, Semaglutide H
- Where
- 2 sites in Canada, Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
T2DM
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional).
- Trial name
- NCT05996380
- Testing
- SHR-3167
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers.
- Trial name
- NCT00501683
- Testing
- Radiolabelled GSK189075
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
This study is conducted in Asia. The aim of this observational study is to evaluate the safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin Aspart under routine clinical practice conditions in…
- Trial name
- NCT00834262
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70
- Where
- Israel
- Volunteers
- 339 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
- Trial name
- NCT00135083
- Testing
- insulin glulisine
- Volunteers
- 347 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study in Adults With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
- Trial name
- ELEMENT 2 (NCT01421459)
- Testing
- LY2963016, Lantus, OAMs
- Where
- 62 sites in United States, Czechia and 10 more
- Volunteers
- 759 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
- Trial name
- NCT07465224
- Testing
- ALN-4324
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects.
- Trial name
- NCT02151461
- Testing
- Low Metformin, Metformin, Mid Metformin
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- NuSirt Biopharma
T2DM (Type 2 Diabetes Mellitus)
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition
- Trial name
- NCT04706286
- Testing
- CKD-501, D759, D150, CKD-393 0.5/100/1000 mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical